Itraconazol Unisens

Itraconazole, the active ingredient in Itraconazol Unisens, is an azole antifungal presented as an oral formulation for systemic use. It is used to treat a range of systemic mycoses, including aspergillosis, candidiasis and dermatophyte infections, in adult patients. The medication is prescribed for individuals who need systemic antifungal therapy and is administered under medical supervision.\nGNH India supplies Itraconazol Unisens as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide across multiple continents.

Itraconazole is an azole antifungal that targets fungal infections by inhibiting ergosterol synthesis, making it effective for several systemic mycoses.\n- Aspergillosis: effective in treating invasive aspergillosis and related pulmonary infections.\n- Candidiasis: used for systemic candidemia and deep‑tissue candidal infections.\n- Dermatophyte infections: treats extensive or refractory dermatophyte infections affecting skin, hair and nails.

Itraconazole may cause a range of adverse reactions, varying from mild to severe.\nCommon Side Effects:\n- Nausea: mild stomach upset.\n- Headache: transient cranial pain.\n- Rash: skin redness or itching.\n- Taste disturbance: altered taste perception.\nSerious or Rare Side Effects:\n- Hepatotoxicity: elevated liver enzymes or liver injury.\n- Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.\n- Cardiac failure: worsening of congestive heart failure.

When prescribing itraconazole, clinicians should observe several precautionary measures to minimize risk.\n- Liver function monitoring: check baseline and periodic liver enzymes during therapy.\n- Drug interaction assessment: review concomitant medications for CYP3A4 substrates or inhibitors.\n- Cardiac status evaluation: avoid use in patients with existing congestive heart failure.\n- Hypersensitivity caution: discontinue if signs of allergic reaction such as rash or swelling appear.\n- Dose adjustment in hepatic impairment: consider reduced dose or alternative therapy in moderate to severe liver disease.\n- Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Itraconazole interacts with several medicines, primarily through CYP3A4 modulation, requiring careful management.\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir): may increase itraconazole levels and toxicity.\n- Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy by lowering drug concentrations.\n- Certain statins (e.g., simvastatin, lovastatin): risk of severe myopathy due to increased statin exposure.\nModerate Interactions (Monitor Closely):\n- Warfarin: itraconazole can enhance anticoagulant effect, requiring INR monitoring.\n- Oral hypoglycemics (e.g., sulfonylureas): may increase risk of hypoglycemia.\n- Proton pump inhibitors: may affect absorption of itraconazole capsules.